Searched for
DRUG MAKER LUPIN
Stocks in news: Hero MotoCorp, Canara Bank, Bharti Airtel, Indian Hotels, SBIIndian markets opened positively, with analysts suggesting a stock-specific strategy amidst consolidation. Hero MotoCorp sees a revival in ...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Lupin receives USFDA EIR for Goa facility with VAI statusDrug maker Lupin said it has received an Establishment Inspection Report from the US Food and Drug Administration for its Goa-based manufac...
- Lupin gets USFDA nod for generic medicationIndian drug maker Lupin has received tentative approval from the US Food and Drug Administration (FDA) to market a generic medication used ...
- USFDA issues Form-483 with 8 observations to Lupin's drug, API production facilities in Mandideep plantThe USFDA had inspected the Mandideep Unit-1 facility in Madhya Pradesh from November 14, 2022, to November 23, 2022, the Mumbai-based drug...
- Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...
- Lupin announces USFDA acceptance for a biosimilar applicationThe pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...
- Lupin Q4 results: Net profit increases by 18% at Rs 460 crore; FY21 profit at Rs 1,216 croreThe company's total income from operations however declined to Rs 3,783 crore during the fourth quarter, as compared to Rs 3,846 crore in t...
- Lupin launches Be One, an ayurvedic energy supplement for menIt is scientifically tested and contains 100 per cent ayurvedic natural ingredients including ashwagandha, shatavari and shilajit that boos...
- Biocon puts arthritis drug on backburnerBiocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.
- Lupin arm buys branded drugs from Japan’s ShionogiThe new branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS (central nerv...
- Lupin launches generic diabetes drug in the USLupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF product...
- Lupin to file new drug application for GSK’s $8 bn blockbuster inhaler AdvairMumbai-based drug maker Lupin Pharma will file an Abbreviated New Drug Application for GSK’s $8-billion dry powder inhaler Advair, said Vin...
- Lupin to challenge Pregabalin ruling by US courtLupin Limited says it will challenge a US court order that prevents it from selling a low-cost generic version of Pfizer's nerve pain drug ...
- Lupin eyes USD 300 mn revenues from Japan in next 2 yearsDrug maker Lupin is eyeing a jump of over 80 per cent in its revenues to $300 million (about Rs 1,557 crore) from the Japanese market in th...
- Lupin aims to break into top 5 in Japanese marketDrug maker Lupin today said it is aiming to become one of the top five generic pharmaceutical companies in Japan in the next three years.
- Lupin gets US FDA nod for anti-depressantDrug maker Lupin has received US Food and Drug Association (FDA) approval for anti-depressant, it said on Wednesday.
- Lupin gets FDA nod for Levetiracetam TabletsDomestic drug maker Lupin on Friday announced that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received the final approval for...
Load More
